Individualized Immunotherapy Approaches in Precision Medicine

Md. Kamrul Hasan Chowdhury ¹, Md Shamsuddin Sultan Khan ²

Individualized immunotherapy in precision medicine revolutionizes treatments based on unique immunological profiles, promising targeted therapies across medical disciplines.

Abstract

In the field of precision medicine, individualized immunotherapy is a paradigm shift that provides customized therapeutic methods based on the unique immunological profiles of patients. This method acknowledges that each person’s immune response is unique and that treating complicated diseases—especially those involving cancer and autoimmune disorders—may not be best served by a one-size-fits-all approach. The search for biomarkers that can forecast a patient’s reaction to particular treatments is one of the main tenets of personalized immunotherapy. Clinicians can gain a more individualized understanding of how the immune system interacts with diseases by detecting molecular and genetic signatures within a patient’s immune system. By using this data, immunotherapies that are most likely to be beneficial for a certain patient are chosen, reducing the need for trial-and-error procedures and their possible side effects. Highly-throughput technology and recent developments in genetics have made personalized immunotherapy a viable option. The creation of tailored cancer vaccines has been made possible by the identification of neoantigens, tumor-specific antigens resulting from mutations, made possible by the effective analysis of vast datasets. Furthermore, the development of CRISPR gene-editing technology has made it possible to modify immune cells to improve their ability to target particular illnesses.In summary, tailored immunotherapy has the potential to completely transform precision medicine’s therapeutic approach. Realizing the full promise of individualized immunotherapies across multiple medical disciplines will depend on our ability to traverse the challenges of using the immune system for therapeutic reasons. This will require both technological advancements and a deeper understanding of individual immunological profiles.

Keywords: Cancer Vaccines,Biomarkers, Precision Medicine, Personalized Treatments.

References

Alderton GK (2012) Tumour immunology: Suppressing tumorigenic inflammation. Nat Rev Cancer 12: 228.

Aspinall, M. G., & Hamermesh, R. G. (2010). Realizing the promise of personalized medicine. Harvard business review, 85(10), 108.

Bakker, J. A., Drent, M., & Bierau, J. (2015). Relevance of pharmacogenetic aspects of mercaptopurine metabolism in the treatment of interstitial lung disease. Current opinion in pulmonary medicine, 13(5), 458-463.

Bhatia S, Tykodi SS, Thompson JA (2009) Treatment of metastatic melanoma: An overview. Oncology SSSS23: 488-496

Ciardiello, F., Adams, R., Tabernero, J., Seufferlein, T., Taieb, J., Moiseyenko, V., ... & Tejpar, S. (2016). Awareness, understanding, and adoption of precision medicine to deliver personalized treatment for patients with cancer: a multinational survey comparison of physicians and patients. The oncologist, 21(3), 292-300.

Ciardiello, F., Arnold, D., Casali, P. G., Cervantes, A., Douillard, J. Y., Eggermont, A., ... & Stahel, R. (2014). Delivering precision medicine in oncology today and in future—the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO). Annals of Oncology, 25(9), 1673-1678.

Coley WB (2018) The treatment of malignant tumours by repeated inoculations of erysipelas with a report of ten original cases. Am J Med Sci 105: 487.

Collins, F. S., & Varmus, H. (2015). A new initiative on precision medicine. New England journal of medicine, 372(9), 793-795.

Daly, B., Zon, R. T., Page, R. D., Edge, S. B., Lyman, G. H., Green, S. R., ... & Bosserman, L. D. (2018). Oncology clinical pathways: charting the landscape of pathway providers. Journal of oncology practice, 14(3), e194-e200.

De Leon, J. (2009). Pharmacogenomics: the promise of personalized medicine for CNS disorders. Neuropsychopharmacology, 34(1), 159-172.

Deverka, P. A., & McLeod, H. L. (2018). Harnessing economic drivers for successful clinical implementation of pharmacogenetic testing. Clinical Pharmacology & Therapeutics, 84(2), 191-193.

Feng K, Guo Y, Dai H, Wang Y, Li X, et al. (2016) Chimeric antigen receptormodified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. Sci China Life Sci 59: 468-479.

Ferris, R. L., Blumenschein Jr, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., … & Gillison, M. L. (2016). Nivolumab for recurrent squamous-cell carcinoma of the head and neck. New England Journal of Medicine, 375(19), 1856-1867.

Flockhart, D. A., O’Kane, D., Williams, M. S., Watson, M. S., Gage, B., Gandolfi, R., … & Veenstra, D. (2018). Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genetics in Medicine, 10(2), 139-150.

Giuse, N. B., Kusnoor, S. V., Koonce, T. Y., Naylor, H. M., Chen, S. C., Blasingame, M. N., ... & Lovly, C. M. (2016). Guiding oncology patients through the maze of precision medicine. Journal of health communication, 21(sup1), 5-17.

Gray, S. W., Hicks-Courant, K., Lathan, C. S., Garraway, L., Park, E. R., & Weeks, J. C. (2012). Attitudes of patients with cancer about personalized medicine and somatic genetic testing. Journal of oncology practice, 8(6), 329-335.

Gunturu, K. S., Woo, Y., Beaubier, N., Remotti, H. E., & Saif, M. W. (2013). Gastric cancer and trastuzumab: first biologic therapy in gastric cancer. Therapeutic advances in medical oncology, 5(2), 143-151.

Gupta, A., Viswanatha, D. S., & Patnaik, M. M. (2017). FLT3 mutation testing in acute myeloid leukemia. JAMA oncology, 3(7), 991-992.

Hermitte F (2016) Biomarkers immune monitoring technology primer: Immunoscore(R) Colon. J Immunother Cancer 4: 57.

Hill, C. E., & Duncan, A. (2010). Overview of pharmacogenetics in anticoagulation therapy. Clinics in laboratory medicine, 28(4), 513-524.

Jameson, J. L., & Longo, D. L. (2015). Precision medicine—personalized, problematic, and promising. Obstetrical & gynecological survey, 70(10), 612-614.

Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, et al. (2012) An immuneactive tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 61: 1019-1031.

Jin C, Yu D, Essand M (2016) Prospects to improve chimeric antigen receptor T-cell therapy for solid tumors. Immunotherapy 8: 1355-1361.

Kakimi, K., Karasaki, T., Matsushita, H., & Sugie, T. (2017). Advances in personalized cancer immunotherapy. Breast Cancer, 24, 16-24.

Kirkwood, M. K., Hanley, A., Bruinooge, S. S., Garrett-Mayer, E., Levit, L. A., Schenkel, C., ... & Schilsky, R. L. (2018). The state of oncology practice in America, 2018: results of the ASCO practice census survey. Journal of Oncology Practice, 14(7), e412-e420.

Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, et al. (2008) High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma:A retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 113: 293-301.

Leach DR, Krummel MF, Allison JP (2016) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271: 1734-1736

Levis, M. (2017). Midostaurin approved for FLT3-mutated AML. Blood, The Journal of the American Society of Hematology, 129(26), 3403-3406.

Levit, L. A., Kim, E. S., McAneny, B. L., Nadauld, L. D., Levit, K., Schenkel, C., & Schilsky, R. L. (2019). Implementing precision medicine in community-based oncology programs: Three models. Journal of oncology practice, 15(6), 325-329.

Madadi, P., Ross, C. J. D., Hayden, M. R., Carleton, B. C., Gaedigk, A., Leeder, J. S., & Koren, G. (2014). Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case–control study. Clinical Pharmacology & Therapeutics, 85(1), 31-35.

Majumder B, Ulaganathan B, Thayakumar A, Thiyagarajan S, Brijwani N, et al. (2015) Identification of responders for Anti-CTLA4 in refractory colorectal cancers using CANScript™ platform. Cancer Res 75: 1304.

Manolopoulos, V. G. (2012). Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice.

Marchiano, E. J., Birkeland, A. C., Swiecicki, P. L., Spector-Bagdady, K., & Shuman, A. G. (2018). Revisiting expectations in an era of precision oncology. The oncologist, 23(3), 386-388.

Mellman, I., Hubbard-Lucey, V. M., Tontonoz, M. J., Kalos, M. D., Chen, D. S., Allison, J. P., ... & Hwu, P. (2016). De-risking immunotherapy: report of a consensus workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute. Cancer immunology research, 4(4), 279-288.

Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, et al. (2016) Integrative Analyses of colorectal cancer show immunoscore is a stronger predictor of Patient survival than microsatellite instability. Immunity 44: 698-711.

Moscow, J. A., Fojo, T., & Schilsky, R. L. (2018). The evidence framework for precision cancer medicine. Nature reviews Clinical oncology, 15(3), 183-192.

Myers, M. B. (2016). Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives. Pharmacogenomics and Personalized Medicine, 7-16.

Nadauld, L. D., Ford, J. M., Pritchard, D., & Brown, T. (2018). Strategies for clinical implementation: precision oncology at three distinct institutions. Health affairs, 37(5), 751-756.

Onea AS, Jazirehi AR (2016) CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin’s Lymphomas. Am J Cancer Res 6: 403-424.

Prasad, V. (2016). Perspective: the precision-oncology illusion. Nature, 537(7619), S63-S63.

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csoszi T, et al. (2016) Pembrolizumab versus chemotherapy for PD-L1-Positive non-small-cell lung cancer. N Engl J Med 375: 1823-1833.

Rusch, V., Klimstra, D., Venkatraman, E., Pisters, P. W., Langenfeld, J., & Dmitrovsky, E. (1997). Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clinical cancer research: an official journal of the American Association for Cancer Research, 3(4), 515-522.

Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012). Diagnosing the decline in pharmaceutical R&D efficiency. Nature reviews Drug discovery, 11(3), 191-200.

Schilsky, R. L. (2014). Implementing personalized cancer care. Nature reviews Clinical oncology, 11(7), 432-438.

Schwartzberg, L., Kim, E. S., Liu, D., & Schrag, D. (2017). Precision oncology: who, how, what, when, and when not?. American Society of Clinical Oncology Educational Book, 37, 160-169.

Seidman, E. G., & Furst, D. E. (2012). Pharmacogenetics for the individualization of treatment of rheumatic disorders using azathioprine. The Journal of Rheumatology, 29(12), 2484-2487.

Sethi, S., Ali, S., Philip, P. A., & Sarkar, F. H. (2013). Clinical advances in molecular biomarkers for cancer diagnosis and therapy. International journal of molecular sciences, 14(7), 14771-14784.

Sgambato, A., Casaluce, F., Maione, P., Rossi, A., Rossi, E., Napolitano, A., … & Gridelli, C. (2012). The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung cancer patients harboring EGFR mutation. Current medicinal chemistry, 19(20), 3337-3352.

Siegel, R. L., Miller, K. D., & Jemal, A. (2018). Cancer statistics, 2018. CA: a cancer journal for clinicians, 68(1), 7-30.

Spitzer, M. H., Carmi, Y., Reticker-Flynn, N. E., Kwek, S. S., Madhireddy, D., Martins, M. M., … & Engleman, E. G. (2017). Systemic immunity is required for effective cancer immunotherapy. Cell, 168(3), 487-502.

Stevanovic S, Draper LM, Langhan MM, Campbell TE, Kwong ML, et al. (2015) Complete regression of metastatic cervical cancer after treatment with human papillomavirus–targeted tumor-infiltrating T cells. J Clin Oncol 33: 1543-1550

Walker, A. R., Wang, H., Walsh, K., Bhatnagar, B., Vasu, S., Garzon, R., … & Marcucci, G. (2016). Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia. Leukemia & lymphoma, 57(9), 2100-2108.

Waters, T. M., Webster, J. A., Stevens, L. A., Li, T., Kaplan, C. M., Graetz, I., & McAneny, B. L. (2015). Community oncology medical homes: Physician-driven change to improve patient care and reduce costs. Journal of oncology practice, 11(6), 462-467.

Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., ... & Riely, G. J. (2013). Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clinical cancer research, 19(8), 2240-2247.